Revenue: As of FY2026 Q1, the actual value is USD 65.84 M, beating the estimate of USD 53 M.EPS: As of FY2026 Q1, the actual value is USD -0.02, beating the estimate of USD -0.0875.EBIT: As of FY2026 Q1, the actual value is USD 1.718 M.Maravai LifeSciences Holdings, Inc. reported its financial results for the first quarter ended March 31, 2026, showing significant improvements across several metrics.<h4>Segment Revenue</h4>Total revenue for Q1 2026 was $65,837 thousand, marking a 40.5% year-over-year increase from $46,850 thousand in Q1 2025. The TRILINK segment revenue reached $47,476 thousand for Q1 2026, growing by 65.1% year-over-year from $28,750 thousand in Q1 2025, primarily due to $14.3 million in high-volume CleanCap orders for commercial phase COVID vaccine programs. Excluding COVID CleanCap revenue, TriLink base revenue increased by 15.4% year-over-year. The CYGNUS segment revenue was $18,361 thousand for Q1 2026, a 1.4% year-over-year increase from $18,100 thousand in Q1 2025, driven by strong demand in North America and EMEA, partially offset by lower contribution from China.<h4>Operational Metrics</h4>Net loss for Q1 2026 was - $6,377 thousand, a substantial improvement from - $52,853 thousand in Q1 2025. Net loss attributable to Maravai LifeSciences Holdings, Inc. was - $3,733 thousand for Q1 2026, compared to - $29,945 thousand for Q1 2025. Adjusted EBITDA (non-GAAP) was $20,327 thousand for Q1 2026, a significant increase from - $10,549 thousand for Q1 2025. Gross profit rose to $33,701 thousand for Q1 2026, up from $7,725 thousand for Q1 2025. Loss from operations improved to - $2,158 thousand for Q1 2026, compared to - $49,162 thousand for Q1 2025. Total operating expenses decreased to $35,859 thousand for Q1 2026 from $56,887 thousand for Q1 2025. Selling, general and administrative expenses were $29,092 thousand for Q1 2026, compared to $39,564 thousand for Q1 2025, while research and development expenses were $3,889 thousand for Q1 2026, down from $4,888 thousand for Q1 2025. Restructuring costs were $2,878 thousand for Q1 2026, and goodwill impairment was - $0 for Q1 2026, a notable change from $12,435 thousand for Q1 2025. Adjusted Net Income (Loss) (non-GAAP) was $3,837 thousand for Q1 2026, compared to - $20,436 thousand for Q1 2025.<h4>Cash Flow</h4>Net cash provided by operating activities was $8,665 thousand for Q1 2026, a positive shift from net cash used in operating activities of - $9,390 thousand for Q1 2025. Purchases of property and equipment amounted to - $4,437 thousand for Q1 2026, compared to - $4,501 thousand for Q1 2025. Free cash flow (non-GAAP) returned to positive at $4,228 thousand for Q1 2026, significantly improving from - $13,891 thousand for Q1 2025.<h4>Unique Metrics</h4>Base revenue, excluding high-volume CleanCap for commercialized COVID-19 vaccines, was up 10% from the prior year. TriLink Base, Non-COVID Revenue grew 15% year over year.<h4>Outlook / Guidance</h4>Maravai LifeSciences Holdings, Inc. increased its full-year 2026 guidance for both revenue and Adjusted EBITDA (non-GAAP). Revenue is now expected to be between $205.0 million and $215.0 million, up from the previous range of $200.0 million to $210.0 million. Adjusted EBITDA (non-GAAP) is projected to be between $30.0 million and $32.0 million, an increase from the prior range of $18.0 million to $20.0 million.

Maravai LifeSciences | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 65.84 M